Flexion Therapeutics Inc

NASDAQ:FLXN   3:39:03 PM EDT
6.26
-0.19 (-2.95%)
Products, Other Pre-Announcement

Flexion Therapeutics Announces Expansion Of Phase 1B Trial Investigating Fx301 For The Management Of Post-Operative Pain

Published: 08/25/2021 13:43 GMT
Flexion Therapeutics Inc (FLXN) - Flexion Therapeutics Announces Expansion of Phase 1b Trial Investigating Fx301 for the Management of Post-operative Pain.
Flexion Therapeutics - Decision to Advance Fx301 Into Expansion Cohort Follows a Review of Safety Data From Single Ascending Dose Stage of Trial.
Flexion Therapeutics - in Expansion Cohort, an Additional 36 Patients Will Be Randomized to Receive Either Fx301 at Selected Dose Or Placebo.
Flexion Therapeutics - Data From Phase1b Fx301 Trial, Including Expansion Cohort, Anticipated by Year-end.